2024 study suggests blood-based MRD tests for colorectal cancer recurrence could save 21% in health plan costs by identifying stage II patients who can avoid chemotherapy.
A study suggests blood-based MRD tests for colorectal cancer recurrence could save up to 21% in health plan costs. By testing stage II patients, ctDNA MRD tests can help identify those who can avoid chemotherapy without compromising recurrence-free survival, potentially reducing healthcare costs and adverse events related to chemotherapy. Results will be presented at the American Society of Clinical Oncology meeting in 2024.
May 31, 2024
3 Articles